Liver Cancer : Impact Factor & More
eISSN: 1664-5553pISSN: 2235-1795
Open AccessShare this on:
Key Metrics
CiteScore 
12.6
H-Index
48
Impact Factor
10 - 15
SJR
Q1Oncology
SNIP
2.38
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Liver Cancer
Liver Cancer Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | KARGER |
| Language | English |
| Frequency | Bi-monthly |
| Article Processing Charges | EUR 3260 | USD 3770 | CHF 3390 |
| Publication Time | 23 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Eastern & Western Association Liver Tumors |
| Frequency | Bi-monthly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Liver Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Liver Cancer
Addition of Intra-arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study
- 5 May 2026
- Liver Cancer
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis
- 24 Apr 2026
- Liver Cancer
Oncological Outcomes and Treatment Strategies for Borderline Resectable Hepatocellular Carcinoma Based on the Oncological Resectability Classification
- 31 Mar 2026
- Liver Cancer
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.
- 30 Mar 2026
- Liver cancer
Imaging-based Liver Transplant Eligibility in HCC: Analysis of 1,094 Patients Using LI-RADS and Asia-Pacific Guideline-based Criteria
- 25 Mar 2026
- Liver Cancer
Efficacy of nivolumab plus ipilimumab in advanced hepatocellular carcinoma with and without high-risk features: an international multicenter study
- 23 Mar 2026
- Liver Cancer
Addition of Intra-arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study
- 5 May 2026
- Liver Cancer
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis
- 24 Apr 2026
- Liver Cancer
Oncological Outcomes and Treatment Strategies for Borderline Resectable Hepatocellular Carcinoma Based on the Oncological Resectability Classification
- 31 Mar 2026
- Liver Cancer
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma.
- 30 Mar 2026
- Liver cancer
Imaging-based Liver Transplant Eligibility in HCC: Analysis of 1,094 Patients Using LI-RADS and Asia-Pacific Guideline-based Criteria
- 25 Mar 2026
- Liver Cancer
Efficacy of nivolumab plus ipilimumab in advanced hepatocellular carcinoma with and without high-risk features: an international multicenter study
- 23 Mar 2026
- Liver Cancer
FAQs on Liver Cancer
How long has Liver Cancer been actively publishing? 
What is the publishing frequency of Liver Cancer?
How many articles did Liver Cancer publish last year?
What is the eISSN & pISSN for Liver Cancer?
What is Citescore for Liver Cancer?
What is the H Index for Liver Cancer ?
What is SNIP score for Liver Cancer?
What is the SJR for Liver Cancer?
Who is the publisher of Liver Cancer?
